114 related articles for article (PubMed ID: 33801595)
1. Prognostic Evidence of the miRNA-Based Ovarian Cancer Signature MiROvaR in Independent Datasets.
De Cecco L; Bagnoli M; Chiodini P; Pignata S; Mezzanzanica D
Cancers (Basel); 2021 Mar; 13(7):. PubMed ID: 33801595
[TBL] [Abstract][Full Text] [Related]
2. Validation of MiROvaR, a microRNA-based predictor of early relapse in early stage epithelial ovarian cancer as a new strategy to optimise patients' prognostic assessment.
Ditto A; De Cecco L; Paolini B; Alberti P; Martinelli F; Leone Roberti Maggiore U; Bogani G; Chiodini P; Pignata S; Tomassetti A; Raspagliesi F; Mezzanzanica D; Bagnoli M
Eur J Cancer; 2022 Jan; 161():55-63. PubMed ID: 34922264
[TBL] [Abstract][Full Text] [Related]
3. Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study.
Bagnoli M; Canevari S; Califano D; Losito S; Maio MD; Raspagliesi F; Carcangiu ML; Toffoli G; Cecchin E; Sorio R; Canzonieri V; Russo D; Scognamiglio G; Chiappetta G; Baldassarre G; Lorusso D; Scambia G; Zannoni GF; Savarese A; Carosi M; Scollo P; Breda E; Murgia V; Perrone F; Pignata S; De Cecco L; Mezzanzanica D;
Lancet Oncol; 2016 Aug; 17(8):1137-1146. PubMed ID: 27402147
[TBL] [Abstract][Full Text] [Related]
4. Association between miR-200c and the survival of patients with stage I epithelial ovarian cancer: a retrospective study of two independent tumour tissue collections.
Marchini S; Cavalieri D; Fruscio R; Calura E; Garavaglia D; Fuso Nerini I; Mangioni C; Cattoretti G; Clivio L; Beltrame L; Katsaros D; Scarampi L; Menato G; Perego P; Chiorino G; Buda A; Romualdi C; D'Incalci M
Lancet Oncol; 2011 Mar; 12(3):273-85. PubMed ID: 21345725
[TBL] [Abstract][Full Text] [Related]
5. miRNA-200a/c as potential biomarker in epithelial ovarian cancer (EOC): evidence based on miRNA meta-signature and clinical investigations.
Teng Y; Su X; Zhang X; Zhang Y; Li C; Niu W; Liu C; Qu K
Oncotarget; 2016 Dec; 7(49):81621-81633. PubMed ID: 27835595
[TBL] [Abstract][Full Text] [Related]
6. A prognostic regulatory pathway in stage I epithelial ovarian cancer: new hints for the poor prognosis assessment.
Calura E; Paracchini L; Fruscio R; DiFeo A; Ravaggi A; Peronne J; Martini P; Sales G; Beltrame L; Bignotti E; Tognon G; Milani R; Clivio L; Dell'Anna T; Cattoretti G; Katsaros D; Sartori E; Mangioni C; Ardighieri L; D'Incalci M; Marchini S; Romualdi C
Ann Oncol; 2016 Aug; 27(8):1511-9. PubMed ID: 27194815
[TBL] [Abstract][Full Text] [Related]
7. lncRNAs as Novel Indicators of Patients' Prognosis in Stage I Epithelial Ovarian Cancer: A Retrospective and Multicentric Study.
Martini P; Paracchini L; Caratti G; Mello-Grand M; Fruscio R; Beltrame L; Calura E; Sales G; Ravaggi A; Bignotti E; Odicino FE; Sartori E; Perego P; Katsaros D; Craparotta I; Chiorino G; Cagnin S; Mannarino L; Ceppi L; Mangioni C; Ghimenti C; D'Incalci M; Marchini S; Romualdi C
Clin Cancer Res; 2017 May; 23(9):2356-2366. PubMed ID: 27827314
[No Abstract] [Full Text] [Related]
8. Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis.
Zhang JX; Song W; Chen ZH; Wei JH; Liao YJ; Lei J; Hu M; Chen GZ; Liao B; Lu J; Zhao HW; Chen W; He YL; Wang HY; Xie D; Luo JH
Lancet Oncol; 2013 Dec; 14(13):1295-306. PubMed ID: 24239208
[TBL] [Abstract][Full Text] [Related]
9. microRNA-494 is a potential prognostic marker and inhibits cellular proliferation, migration and invasion by targeting SIRT1 in epithelial ovarian cancer.
Yang A; Wang X; Yu C; Jin Z; Wei L; Cao J; Wang Q; Zhang M; Zhang L; Zhang L; Hao C
Oncol Lett; 2017 Sep; 14(3):3177-3184. PubMed ID: 28927063
[TBL] [Abstract][Full Text] [Related]
10. Identification and validation of potential prognostic and predictive miRNAs of epithelial ovarian cancer.
Prahm KP; Høgdall C; Karlsen MA; Christensen IJ; Novotny GW; Høgdall E
PLoS One; 2018; 13(11):e0207319. PubMed ID: 30475821
[TBL] [Abstract][Full Text] [Related]
11. Establishment and validation of a novel autophagy-related gene signature for patients with breast cancer.
Du JX; Chen C; Luo YH; Cai JL; Cai CZ; Xu J; Ni XJ; Zhu W
Gene; 2020 Dec; 762():144974. PubMed ID: 32707305
[TBL] [Abstract][Full Text] [Related]
12. Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers.
Lane D; Matte I; Garde-Granger P; Laplante C; Carignan A; Rancourt C; Piché A
BMC Cancer; 2015 Jul; 15():492. PubMed ID: 26122176
[TBL] [Abstract][Full Text] [Related]
13. Expression profiles of PRKG1, SDF2L1 and PPP1R12A are predictive and prognostic factors for therapy response and survival in high-grade serous ovarian cancer.
Benvenuto G; Todeschini P; Paracchini L; Calura E; Fruscio R; Romani C; Beltrame L; Martini P; Ravaggi A; Ceppi L; Sales G; Donati F; Perego P; Zanotti L; Ballabio S; Grassi T; Delle Marchette M; Tognon G; Sartori E; Adorni M; Odicino F; D'Incalci M; Bignotti E; Romualdi C; Marchini S
Int J Cancer; 2020 Jul; 147(2):565-574. PubMed ID: 32096871
[TBL] [Abstract][Full Text] [Related]
14. HE4 expression in plasma correlates with surgical outcome and overall survival in patients with first ovarian cancer relapse.
Braicu EI; Chekerov R; Richter R; Pop C; Nassir M; Loefgren H; Stamatian F; Muallem MZ; Hall C; Fotopoulou C; Sehouli J; Pietzner K
Ann Surg Oncol; 2014 Mar; 21(3):955-62. PubMed ID: 24217786
[TBL] [Abstract][Full Text] [Related]
15. Potential biomarker of circulating hsa-miR-1273g-3p level for detection of recurrent epithelial ovarian cancer.
Günel T; Gumusoglu E; Dogan B; Ertem FB; Hosseini MK; Cevik N; Senol T; Topuz S; Aydinli K
Arch Gynecol Obstet; 2018 Dec; 298(6):1173-1180. PubMed ID: 30264202
[TBL] [Abstract][Full Text] [Related]
16. A Novel Two-Lipid Signature Is a Strong and Independent Prognostic Factor in Ovarian Cancer.
Salminen L; Braicu EI; Lääperi M; Jylhä A; Oksa S; Hietanen S; Sehouli J; Kulbe H; Bois AD; Mahner S; Harter P; Carpén O; Huhtinen K; Hynninen J; Hilvo M
Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33917079
[TBL] [Abstract][Full Text] [Related]
17. Preoperative albumin-to-fibrinogen ratio predicts chemotherapy resistance and prognosis in patients with advanced epithelial ovarian cancer.
Yu W; Ye Z; Fang X; Jiang X; Jiang Y
J Ovarian Res; 2019 Sep; 12(1):88. PubMed ID: 31533857
[TBL] [Abstract][Full Text] [Related]
18. Preoperative neutrophil-to-lymphocyte ratio is a predictor of survival of epithelial ovarian cancer: a systematic review and meta-analysis of observational studies.
Yang Z; Gu JH; Guo CS; Li XH; Yang WC
Oncotarget; 2017 Jul; 8(28):46414-46424. PubMed ID: 28423365
[TBL] [Abstract][Full Text] [Related]
19. Identification of a three-miRNA signature as a novel potential prognostic biomarker in patients with clear cell renal cell carcinoma.
Luo Y; Chen L; Wang G; Xiao Y; Ju L; Wang X
J Cell Biochem; 2019 Aug; 120(8):13751-13764. PubMed ID: 30957284
[TBL] [Abstract][Full Text] [Related]
20. Identifying a new microRNA signature as a prognostic biomarker in colon cancer.
Lv Y; Duanmu J; Fu X; Li T; Jiang Q
PLoS One; 2020; 15(2):e0228575. PubMed ID: 32049961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
